| Population 2016 |
<1 million |
| |
| | | | | |
| Estimates of TB burden*, 2016 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
<0.01 |
(<0.01–<0.01) |
0.19 |
(0.17–0.2) |
| Mortality (HIV+TB only) |
<0.01 |
(<0.01–<0.01) |
0 |
(0–0.01) |
| Incidence (includes HIV+TB) |
0.1 |
(0.086–0.12) |
16 |
(14–18) |
| Incidence (HIV+TB only) |
0 |
(0–0) |
0.03 |
(0.02–0.03) |
| Incidence (MDR/RR-TB)** |
0 |
(0–0) |
0 |
(0–0) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2016 |
| |
0-14 years |
> 14 years |
Total |
| Females |
<0.01 |
(<0.01–<0.01) |
0.029 |
(0.024–0.033) |
0.034 |
(0.029–0.039) |
| Males |
<0.01 |
(<0.01–<0.01) |
0.061 |
(0.051–0.07) |
0.066 |
(0.056–0.076) |
| Total |
0.011 |
(<0.01–0.012) |
0.089 |
(0.076–0.1) |
0.1 |
(0.086–0.12) |
| |
| | | | | |
| TB case notifications, 2016 |
|
| Total cases notified |
87 |
| Total new and relapse |
87 |
| - % tested with rapid diagnostics at time of diagnosis |
29% |
| - % with known HIV status |
69% |
| - % pulmonary |
89% |
| - % bacteriologically confirmed among pulmonary |
75% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2016 |
87% (75–100) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2016 |
0.01 (0.01–0.01) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2016 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
0 |
0% |
| - on antiretroviral therapy |
0 |
|
| |
| | | | | |
| Drug-resistant TB care, 2016 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
0
(0–0) |
| Estimated % of TB cases with MDR/RR-TB |
0% (0–7.1) |
0% (0–41) |
|
| % notified tested for rifampicin resistance |
68% |
50% |
57 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
0 |
| Laboratory-confirmed cases |
MDR/RR-TB: 0, XDR-TB: 1 |
| Patients started on treatment **** |
MDR/RR-TB: 0, XDR-TB: 1 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2015 |
93% |
80 |
| Previously treated cases, excluding relapse, registered in 2015 |
|
0 |
| HIV-positive TB cases registered in 2015 |
|
0 |
| MDR/RR-TB cases started on second-line treatment in 2014 |
0% |
2 |
| XDR-TB cases started on second-line treatment in 2014 |
|
0 |
| |
| | | | | |
| TB preventive treatment, 2016 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
|
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
|
| |
| | | | | |
| TB financing, 2017 |
|
| National TB budget (US$ millions) |
<1 |
| Funding source: 100% domestic, 0% international, 0% unfunded |
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed | | |
| | | | | |